Standard BioTools Statistics
Total Valuation
LAB has a market cap or net worth of $405.98 million. The enterprise value is -$21.65 million.
Important Dates
The last earnings date was Tuesday, May 5, 2026, after market close.
| Earnings Date | May 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
LAB has 390.37 million shares outstanding. The number of shares has increased by 2.63% in one year.
| Current Share Class | 390.37M |
| Shares Outstanding | 390.37M |
| Shares Change (YoY) | +2.63% |
| Shares Change (QoQ) | +0.82% |
| Owned by Insiders (%) | 1.57% |
| Owned by Institutions (%) | 31.78% |
| Float | 210.62M |
Valuation Ratios
The trailing PE ratio is 5.17 and the forward PE ratio is 54.50.
| PE Ratio | 5.17 |
| Forward PE | 54.50 |
| PS Ratio | 4.68 |
| Forward PS | 4.84 |
| PB Ratio | 0.76 |
| P/TBV Ratio | 0.72 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 12.36, with a Debt / Equity ratio of 0.05.
| Current Ratio | 12.36 |
| Quick Ratio | 11.77 |
| Debt / Equity | 0.05 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -3,019.46 |
Financial Efficiency
Return on equity (ROE) is -9.86% and return on invested capital (ROIC) is -9.11%.
| Return on Equity (ROE) | -9.86% |
| Return on Assets (ROA) | -8.05% |
| Return on Invested Capital (ROIC) | -9.11% |
| Return on Capital Employed (ROCE) | -13.15% |
| Weighted Average Cost of Capital (WACC) | 10.70% |
| Revenue Per Employee | $221,735 |
| Profits Per Employee | $201,041 |
| Employee Count | 389 |
| Asset Turnover | 0.14 |
| Inventory Turnover | 1.33 |
Taxes
| Income Tax | -37.75M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +18.27% in the last 52 weeks. The beta is 1.31, so LAB's price volatility has been higher than the market average.
| Beta (5Y) | 1.31 |
| 52-Week Price Change | +18.27% |
| 50-Day Moving Average | 0.95 |
| 200-Day Moving Average | 1.22 |
| Relative Strength Index (RSI) | 66.03 |
| Average Volume (20 Days) | 2,046,937 |
Short Selling Information
The latest short interest is 11.82 million, so 3.03% of the outstanding shares have been sold short.
| Short Interest | 11.82M |
| Short Previous Month | 8.48M |
| Short % of Shares Out | 3.03% |
| Short % of Float | 5.61% |
| Short Ratio (days to cover) | 3.88 |
Income Statement
In the last 12 months, LAB had revenue of $86.26 million and earned $78.21 million in profits. Earnings per share was $0.20.
| Revenue | 86.26M |
| Gross Profit | 45.95M |
| Operating Income | -78.51M |
| Pretax Income | -87.83M |
| Net Income | 78.21M |
| EBITDA | -68.21M |
| EBIT | -78.51M |
| Earnings Per Share (EPS) | $0.20 |
Full Income StatementBalance Sheet
The company has $455.18 million in cash and $29.49 million in debt, with a net cash position of $425.69 million or $1.09 per share.
| Cash & Cash Equivalents | 455.18M |
| Total Debt | 29.49M |
| Net Cash | 425.69M |
| Net Cash Per Share | $1.09 |
| Equity (Book Value) | 561.12M |
| Book Value Per Share | 1.44 |
| Working Capital | 479.25M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$90.66 million and capital expenditures -$3.82 million, giving a free cash flow of -$94.48 million.
| Operating Cash Flow | -90.66M |
| Capital Expenditures | -3.82M |
| Depreciation & Amortization | 10.30M |
| Net Borrowing | n/a |
| Free Cash Flow | -94.48M |
| FCF Per Share | -$0.24 |
Full Cash Flow StatementMargins
Gross margin is 53.27%, with operating and profit margins of -91.02% and 90.67%.
| Gross Margin | 53.27% |
| Operating Margin | -91.02% |
| Pretax Margin | -101.82% |
| Profit Margin | 90.67% |
| EBITDA Margin | -79.08% |
| EBIT Margin | -91.02% |
| FCF Margin | n/a |
Dividends & Yields
LAB does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -2.63% |
| Shareholder Yield | -2.63% |
| Earnings Yield | 19.36% |
| FCF Yield | -23.38% |
Analyst Forecast
The average price target for LAB is $1.55, which is 49.04% higher than the current price. The consensus rating is "Buy".
| Price Target | $1.55 |
| Price Target Difference | 49.04% |
| Analyst Consensus | Buy |
| Analyst Count | 2 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | |
| Graham Upside | |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
LAB has an Altman Z-Score of 1.81 and a Piotroski F-Score of 4. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | 1.81 |
| Piotroski F-Score | 4 |
